Review Article

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes

Nora Chokr,1,2 Rima Patel,3 Kapil Wattamwar,1,2 and Samer Chokr4

1Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
2Waterbury Hospital, Waterbury, CT, USA
3Tufts Medical Center, Boston, MA, USA
4Medical University of Varna, Varna, Bulgaria

Correspondence should be addressed to Nora Chokr; nora.chokr@yale.edu

Received 28 March 2018; Revised 2 August 2018; Accepted 27 September 2018; Published 1 November 2018

Academic Editor: Donna Hogge

Copyright © 2018 Nora Chokr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Several immune mechanisms have been identified in MDS, suggesting that immune dysregulation might be at least partially implicated in its pathogenesis. This has led to rigorous investigations on the role of immunomodulatory drugs as potential treatment options. Epigenetic modification via immune checkpoint inhibition, while well-established as a treatment method for advanced solid tumors, is a new approach being considered in hematologic malignancies including high risk MDS. Several trials are looking at the efficacy of these agents in MDS, as frontline therapy and in relapse, both as monotherapy and in combination with other drugs. In this review, we explore the utility of immune checkpoint inhibitors in MDS and current research evaluating their efficacy.

1. Introduction

Myelodysplastic syndromes (MDS) are a complex set of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations, ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). Most patients are elderly with the vast majority diagnosed after the age of 60 years [1]. According to the World Health Organization (WHO) classification, diagnosis of MDS is still based mostly on histologic and cytologic examination of the bone marrow and peripheral blood. A large number of somatic driver mutations in splicing factors and other epigenetic regulators are thought to have diagnostic and prognostic implications, with the exception of del(5q) and SF3B1 which are mentioned in the classification [2, 3] (Table 1). Patients are risk stratified using several scores including the International Prognostic Scoring System (IPSS), revised IPSS, and the MD Anderson Cancer Center scores. Low risk MDS patients remain stable for years with a 4-year survival rate of 80%, whereas high risk MDS is associated with poor outcomes and rapid progression to leukemia with a median survival of less than a year [2].

Standard of care in MDS includes supportive care with blood transfusions, hematopoietic growth factors, immune modulation with lenalidomide in del(5q), and epigenetic modulation by hypomethylating agents (HMA) such as azacitidine and decitabine. Lenalidomide and HMA have led to a decrease in transfusion dependency and progression to AML. Azacitidine in particular has been associated with an increase in overall survival [4]. However, response to these agents can be lost over time, which emphasizes the importance of gaining a deeper understanding of the disease pathogenesis and development of novel therapies.

2. Immune Mechanisms in MDS

Several studies have shown an association between autoimmune diseases and low risk MDS. People with preexisting
Table 1: Common gene mutations in MDS and the prognostic values [3].

| Genes                     | Prognostic Impact |
|---------------------------|-------------------|
| **Epigenetic Regulators** |                   |
| TET2                      | poor              |
| EZH2                      | poor              |
| ASXL1                     | poor              |
| DNMT3A                    | poor              |
| IDH1/IDH2                 | poor              |
| **Spliceosomal genes**    |                   |
| SF3B1                     | good              |
| U2AF1                     | poor              |
| SRSF2                     | poor              |
| ZRSR2                     | unknown           |
| **Cytoplasmic tyrosine kinases** |           |
| JAK2                      | poor              |
| **Signaling molecules**    |                   |
| SETBP1                    | poor              |
| NRAS                      | poor              |
| **Transcriptional factors** |                 |
| ETV6                      | poor              |
| RUNX1                     | poor              |
| **Tumor suppressors**      |                   |
| TP53                      | poor              |
| ROBO1/ROBO2               | poor              |
| **Chromatid cohesion**    |                   |
| STAG2                     | poor              |

Autoimmune disease have an odds ratio of 1.5 to 3.5 for developing MDS [5–7]. There are several immune based mechanisms identified in MDS, suggesting that immune dysregulation might be at least partially implicated in the pathogenesis of MDS.

At the level of the bone marrow, normal hematopoiesis is regulated by the immune system via a complex interplay between T-cells, cytokines, innate immunity, and mesenchymal stromal cells (MSC) Figure 1. In MDS, immune dysregulation occurs through several mechanisms including T-cell mediated bone marrow suppression, expression of cytokines, overactivation of pathways involved in innate immunity, and altered mesenchymal stromal cells (MSC). We elaborate on each of these mechanisms to better understand the pathogenesis of MDS.

In low risk MDS, apoptosis plays a key role through T-cell inhibition. Many MDS patients have oligoclonal T-cells, largely derived from a malignant MDS clone. These cytotoxic CD8+ T-cells recognize MHC-class I molecules on progenitor cells inhibiting growth and leading to cytopenias and abnormal hematopoiesis. These cytotoxic T-cells carry specific TCR subtypes that intoxicate hematopoietic cells [8, 9]. A study by Wu et al. showed the possible inhibitory function of T-cells was likely due to type-1 polarization involving both the CD-4+ and CD-8+ subsets [10].

Another study has questioned the autoreactivity of T-cells in MDS which was suggested by a defective in vitro cytotoxicity [11]. Overall, studies have shown that cytotoxic T-cells are likely involved in autoimmune reactions towards hematopoietic cells. These immune mechanisms have been further reinforced in trials that showed hematopoietic recovery and delayed progression to AML with immunosuppressive therapies that block the cytotoxic effects of CD8+ lymphocytes [8, 9].

Several cytokines are abnormally expressed in MDS, either by clonal cells or surrounding stromal cells. Tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) are overly expressed in MDS [12–14]. These cytokines increase the expression of Fas receptors (FasR) on hematopoietic cells and enhance their interaction with Fas ligands leading to apoptosis [15]. TNF-α and IFN-γ were shown to induce the immunoinhibitory molecule B7-H1, via nuclear factor-kappa B activation in blasts of MDS patients [16]. The role of TGF-β cytokine in inhibition of normal stem cells is also well established, and its pathway has been recently targeted by several drugs. TGF-β binds to a set of TGF-β receptors and leads to the activation of intracellular SMAD 2/3 proteins [12–15]. The levels of TNF-α and TGF-B are inversely related to hemoglobin and survival [8]. These cytokines also induce the expression of programmed death ligand 1 (PD-L1) on tumor cells, a mechanism that can potentially allow tumor cells to escape from the immune mediated tumor surveillance. CD3+ CD4+ interleukin (IL)-17 producing T-cells have been shown to be upregulated in low risk MDS, and higher levels have been also associated with more severe anemia [17, 18].
Myeloid-derived suppressor cells (MDSC) were shown to be increased in the bone marrow of MDS patients. These cells overproduce cytokines that suppress normal hematopoiesis and induce mechanisms that target hematopoietic progenitors leading to increased apoptosis. The expansion of MDSC results from the interaction of the proinflammatory molecule S100A9 with CD33 and the subsequent production of the proinflammatory cytokines. **Late (high risk MDS).** While continued inflammation leads to more apoptosis of hematopoietic stem cells (HSC) and cytopenias worsen, TNF-α and INF-γ start inducing PD-L1 expression on MDS clonal cells. (7) PD-L1 allows the MDS cells to escape immune surveillance by T-cell suppression. AML. (8) MDS transitions into acute myeloid leukemia (AML).

DC in MDS express lower levels of CD1a, CD54, CD80, and MHC II molecules [26]. Immature DC have an impaired cytokine secretion which likely accounts for their reduced allostimulatory capacity [27].

Normal hematopoiesis is a fine balance that depends not only on the hematopoietic progenitor cells, but also on the surrounding MSC. They play a pivotal role in the birth of MDS clones and other myeloid malignancies. In MDS, MSC may be absent or dysfunctional due to genetic aberrations. The selective deletion of Dicer1 gene in MSC cells of murine models was shown to induce MDS and AML [28]. Research has shown that cytogenetically abnormal MSC in MDS lead to the production of proinflammatory cytokines such as TNF-α, IL-6, TGF-B, and IFN-γ [29, 30]. Normally, MSC exert immunosuppressive effects on the surrounding T-cells through paracrine and cell-to-cell interactions, which then arrests T-cells in the G1-phase and diminishes their cytokine secretion [8,31]. However, this immunosuppressive effect on CD8+ T-cells can become aberrant in MDS. Interestingly, significant differences in the immunoregulatory functions were demonstrated between MSC in low risk MDS versus high risk MDS. In high risk MDS, MSC are characterized by increased TGF-BI expression, apoptosis, immunosuppressive rate, and reduced hematopoietic support ability [31]. MSC in low risk MDS are also characterized by a poor ability to suppress dendritic cells differentiation and maturation [32].
Though these intricate immune mechanisms suggest that immunomodulatory and immunosuppressive therapies can be potential treatment options for MDS, these therapies were interestingly trialed even before the underlying mechanisms were completely understood. Immunosuppressive drugs such as antithymocyte globulin (ATG), cyclosporine (CS), and mycophenolate mofetil (MM) have been studied in low risk MDS [33], but still underutilized in MDS patients due to conflicting data and variable rates of response reported by the different studies [34–36]. Also, MAPK and TLR inhibitors, which target overactive TLR pathways in MDS, are currently being evaluated in several clinical trials [8, 37, 38]. Checkpoint inhibitors are another family of drugs that have been approved for solid tumors and now being investigated in high risk MDS and other hematologic malignancies such as AML [1].

3. The Rise of Immune Checkpoint Inhibitors

The concept of developing therapies targeting the immune system rather than tumor cells originated from Dr. James Allison’s discovery of the cytotoxic T-lymphocyte antigen 4 (CTLA-4), a T-cell receptor that downregulates T-cells and the immune system. This led to the development of ipilimumab (Yervoy, Bristol-Myers Squibb), a human IgG1 CTLA-4 checkpoint inhibitor which blocks T-cell suppression and upregulates antitumor immune defenses [39]. Programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) represent an immune checkpoint involved in regulating T-cells at the level of the peripheral tissues. Tumors can express PD-L1 and use these ligands to evade the host's immune system, making this checkpoint a potential target for cancer therapy [40, 41]. This pathway inspired the development of monoclonal antibodies that block the interaction between PD-1 receptors and PD-L1 ligands to help restore anticancer immune responses [42]. These agents have proven to be very effective in tumors refractory to standard chemotherapy regimens in more than 10 organ systems.

Pembrolizumab (Keytruda, Merck) was the first PD1 inhibitor approved by the US Food and Drug Administration (FDA) in September 2014 for treatment of advanced melanoma refractory to BRAF inhibitors and ipilimumab. Nivolumab (Opdivo, Bristol-Myers Squibb), the fully human IgG4 anti-PD-1 antibody, was approved by the FDA in December 2014 for unresectable or metastatic melanoma that progressed after ipilimumab therapy and for patients with positive BRAF V600 mutation who failed treatment with BRAF inhibitors. The approval came after the landmark clinical trial Checkmate-037 [43]. In addition to melanoma, Nivolumab is now FDA approved for metastatic non-small cell lung cancer, metastatic renal cell carcinoma and urothelial cancers, refractory Hodgkin’s lymphoma, cancers of the head and neck, and hepatocellular carcinoma. Results in non-Hodgkin's lymphoma were favorable in refractory follicular lymphoma. Results in relapsed diffuse large B-cell lymphoma following autologous stem cell transplantation have shown an overall survival probability of 82% at 16 months following treatment with pidilizumab, an experimental PD-1 inhibitor. Monotherapy with anti-PD-1 agents in multiple myeloma has not shown any promising results; however, current trials are studying the effect of anti-PD-1 agents in combination with standard myeloma therapy. Preliminary data from these trials has shown a synergistic effect and higher response rates compared to standard chemotherapy alone [39, 44, 45]. There are several ongoing clinical trials investigating the role of PD-1 blockade in myelodysplastic syndromes as well, either as monotherapy or in combination with other therapies.

The use of checkpoint inhibitors is expected to rise dramatically as we learn more about their efficacy across a wide range of cancers. These medications, however, are not harmless. Some of the adverse effects are mild and easily controlled with systemic steroids, but others can be serious and fatal. In their attempt to augment the immune response, PD-1 inhibitors can breach immunologic tolerance by upregulating autoreactive T-cells causing immune mediated reactions such as rash, pneumonitis, colitis, thyroiditis, hepatitis, nephritis, uveitis, adrenalitis, facial nerve paresis, hypophysitis, aseptic meningitis, and fulminant diabetes [41]. The role of autoimmunity has been recognized as a pathogenic mechanism in low risk MDS but is still under discussion and not clearly delineated. In high risk MDS, the role of autoimmunity is even less so understood. Check point inhibitors should be used with caution in high risk MDS due to their potential autoimmune side effects.

4. MDS and Checkpoint Inhibitors

Epigenetic modification via PD-1 inhibition is a new approach being considered in high risk MDS and other hematologic malignancies. Yang et al. [46] reported abnormal upregulation of PD-L1, PD-L2, PD-1, and CTLA4 in CD34+ cells in MDS patients compared to healthy controls. This may be one of the major mechanisms triggering high risk MDS. Patients with high risk MDS have a higher percentage of PD-L1 expression on their blasts compared to those with low risk MDS. This upregulation of PD-1/PD-L1 is evident not only in the clonal cells but also in their surrounding mesenchymal cells. Dail et al. [47] measured PD-L1 expression using multicolor flow cytometry and immunohistochemistry and found that PD-L1 is detectable in more than 2% of cells in all MDS patients, with the majority of expression occurring in non-tumor hematopoietic cells. This supports that the upregulation of PD-1/PD-L1 occurs in both clonal cells and MSC. The interaction between these cells and PD-1/PD-L1 leads to T-cell suppression and influences cell cycle progression. This also results in genetic and epigenetic modulation leading to increased apoptosis and cancer tolerance [48]. Some of the mechanisms implicated in this T-cell suppression include inhibition of Lck/ZAP-70 and PI3K-Akt/MEK-ERK MAPK pathways, indirect activation of p38 MAPK, increased proliferation of T regulatory cells with suppressor effects on the immune response, and inhibition of T-cell receptor mediated lymphocyte proliferation and cytokine secretion [2].

There are some trials evaluating the role of checkpoint inhibitors as monotherapy in MDS. Garcia-Manero et al. conducted a phase Ib trial to investigate the efficacy and side
effect profile of the PD-1 inhibitor, pembrolizumab, in 28 MDS patients with intermediate 1 or 2 or high risk MDS who failed therapy with HMA. The trial showed favorable outcomes. Efficacy was evaluated in 27 patients using the IWG 2006 response criteria for MDS [49]. Partial response was observed in 1 patient (3%), complete marrow response in 3 patients (11%), and stable disease in 14 patients (52%) and progressive disease was noted in 9 patients (33%). The median overall survival for all patients was 23 weeks, and 4 of the 27 patients were alive for more than 2 years [50]. Adverse effects were noted in 10 of 28 patients with most common effects being fatigue and hypothyroidism. There was one case of grade 3 gastroenteritis and one case of grade 4 tumor lysis syndrome [1].

The CTLA-4 inhibitor, ipilimumab, yielded stabilization of high risk MDS in 5 of 11 patients in a phase Ib study [51]. Zeidan et al. [51] studied the efficacy of ipilimumab in high risk MDS patients who failed HMA in a multicenter phase Ib clinical trial enrolling 29 patients with IPSS intermediate-1 or 2 to high risk. Two complete marrow responses were reported (7%). Prolonged stable disease for 46 weeks or more occurred in 6 patients and for 54 weeks or more in 3 patients. Median overall survival was 294 days and for those who received maintenance ipilimumab, it was 400 days. Patients who responded had increased expression of inducible T-cell costimulator (ICOS), a biomarker of T-cell activation. This trial revealed that the effect of ipilimumab monotherapy while effective in some cases is, however, limited and more combination-based approaches should be considered for more significant response rates.

Since research on checkpoint inhibitors as monotherapy in HMA refractory patients has shown limited response, checkpoint inhibitors are now being studied in combination with other MDS therapies particularly HMA to assess for synergistic response. Wrangle et al. [52] were the first to describe the sensitization effect of HMA to anti-PD-1 agents. They noticed high response rates in non-small cell lung cancer patients who failed treatment with azacitidine and were later enrolled in a trial with a PD-1 inhibitor. HMA were found to induce viral mimicry by upregulating endogenous retroviruses (ERV’s) leading to upregulation of checkpoint pathways, increase in apoptosis, and sensitization of MDS cells to checkpoint inhibitors [53–55]. HMA increase PD-1 expression in peripheral blood mononuclear cells and bone marrow cells [46]. If resistance to HMA is at least partially mediated by the increased activation of checkpoint pathways, then combining both HMA and checkpoint inhibitors should theoretically yield more favorable results. Another mechanism by which HMA increase the sensitivity to PD-1/PD-L1 inhibition is through the suppression of myeloid-derived suppressor cells (MDSCs) in the bone marrow [48]. While HMA are thought to increase sensitivity to PD-1 inhibitors by upregulating PD-1, PD-L1, and PD-L2, it remains unclear if blocking the PD-1/PD-L1 pathway will result in restoring sensitivity to HMA in treatment refractory patients. Garcia-Manero et al. evaluated multiple cohorts that included cohort 1 treated with nivolumab alone, cohort 2 with ipilimumab alone, and cohort 3 with nivolumab combined with ipilimumab. All three cohorts evaluated MDS patients who progressed on HMA therapy. The study also included cohort 4 treated with azacitidine and nivolumab, cohort 5 azacitidine combined with ipilimumab, and cohort 6 azacitidine combined with nivolumab and ipilimumab, all of which were previously untreated intermediate 2 to high risk MDS patients. Cohort 1 that received nivolumab alone did not show any significant response. Cohort 2 that received ipilimumab showed an overall response rate of 30% (5 of 16) with 18% of the patients (3 of 16) experiencing grade 3 or more adverse events related to the therapy [56]. The response rate in cohort 4 that received a combination of azacitidine and nivolumab was 80% (13 of 17). It is noteworthy that in cohort 1, patients received nivolumab alone after failing treatment with HMA and did not have any significant response, whereas the cohort receiving combination therapy with nivolumab and azacitidine had a good response rate, suggesting that both drugs are likely working synergistically. The higher response rate of azacitidine and nivolumab suggest that combination therapy is more effective than nivolumab monotherapy [1]. Data from cohort 6 is not yet available (Table 2).

PD-L1 inhibitors atezolizumab and durvalumab are currently being investigated alone and in combination with HMA [39]. Other ongoing trials in MDS include pembrolizumab in combination with entinostat, a histone deacetylase inhibitor, in HMA refractory patients. Two ongoing phase Ib trials are studying atezolizumab in combination with other agents in previously untreated patients (Table 2).

5. Conclusion

MDS are a complex disease resulting from genetic and epigenetic derangements in clonal cells and their surrounding microenvironment. Over the past 10 years, our deeper understanding of the disease has allowed for great pharmacologic and therapeutic advancements with azacitidine, decitabine, and lenalidomide. Unfortunately, the results are still not optimal. It is not surprising given the involvement of several signaling pathways and underlying mechanisms as patients often do not respond or lose response over time to a specific therapy. There is still a significant knowledge gap that needs to be filled for MDS. Several somatic mutations have been identified in MDS suggesting that precision medicine with targeting of actionable mutations such as IDH1/2, RAS, JAK, and FLT3 may be an attractive approach [57]. One should keep in mind that targeting one specific mutation may only be a short-term solution as clonal cells may develop new escape mechanisms and novel mutations leading to loss of response. We are in need of therapeutic options that can be used in MDS regardless of genomic profiles. Immunotherapy is a new approach that is independent of genomic background [57]. It is unclear whether immune checkpoint inhibitors will provide any benefit as monotherapy. Preliminary data from clinical trials show promising results when these agents are combined with HMA in patients who initially failed HMA monotherapy, suggesting synergistic effect between the drugs. Currently, there are some phase I trials studying the efficacy of checkpoint inhibitors in patients with MDS, both as frontline therapy and in refractory disease [57].
Table 2: Ongoing and future monotherapy and combination phase I/II trials with immune checkpoint inhibitors in MDS and interim results.

| Trials                                                                                                                                   | Authors          | Treatment Arms                        | Estimated MDS Participants | Inclusion Criteria                                                                 | Outcomes                                                                                                  | Comments                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------|------------------|---------------------------------------|----------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| A Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes after Hypomethylating Agent Failure (NCT01757639)             | Zeidan et al     | Ipilimumab alone                      | 29                         | HMA failure* or HMA refusal IPSS int-1 with excess BM blasts ≥ 5% or transfusion dependency, Int-2 or high risk; | mCR 7%; PSD 31%; OS 294 days and 400 days with maintenance                                              | Phase 1                                                                                         |
| Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial | Zeidan et al     | Ipilimumab alone                      | 11                         | Primary or secondary failure of HMAs* IPSS int-1 with excess BM blasts ≥ 5% or transfusion dependency, Int-2 or high risk; | SD >6 m 27.3%; SD >16 m 9%; PSD 9%; median OS 368 d; mean OS 352 d; 3 patients underwent alloSCT and remained in CR at 2,12,18 m post SCT | Showed that 3 mg/kg dose is tolerable and can lead to prolonged disease stabilization; alloSCT is feasible post ipilimumab phase 1 |
| A Phase I Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) (NCT01953692)               | Garcia-Manero et al | Pembrolizumab alone                  | 28                         | HMA failure IPSS int-1, int-2, or high risk                                         | mCR 11%; PR 3%; SD 52%; HI 11%; PD 33%; median OS 23 weeks; 15% alive for >2 years                   | Phase 1                                                                                         |
|                               |                  | Cohort 1 nivolumab alone; Cohort 2 ipilimumab alone; Cohort 3 nivolumab + ipilimumab; Cohort 4 azacitidine + nivolumab; Cohort 5 azacitidine + ipilimumab; Cohort 6 azacitidine + nivolumab + ipilimumab | 120                        | Cohorts 1,2,3 in HMAs failure* in any IPSS risk; Cohorts 4,5,6 frontline therapy in int./high-risk MDS, NR 56%, PD 12%; Cohort 4: ORR 80% (CR 6 of 17, mCR+HI in 6 of 17, HI-P in 1), PD 12% | Data from cohorts 1,2,4 was presented at ASH 2016 phase 2                                               | Limited data available: Cohort 1: No response noted; Cohort 2: ORR 30% (includes CR in 1, mCR in 2, HI in 2) in int/high-risk MDS, NR 56%, PD 12%; Cohort 4: ORR 80% (CR 6 of 17, mCR+HI in 6 of 17, HI-P in 1), PD 12% | Limitation data available: Cohort 1: No response noted; Cohort 2: ORR 30% (includes CR in 1, mCR in 2, HI in 2) in int/high-risk MDS, NR 56%, PD 12%; Cohort 4: ORR 80% (CR 6 of 17, mCR+HI in 6 of 17, HI-P in 1), PD 12% |
| Trials | Authors | Treatment Arms | Estimated MDS Participants | Inclusion Criteria | Outcomes | Comments |
|--------|---------|----------------|-----------------------------|-------------------|----------|----------|
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (NCT02599649) | Garcia Manero et al | Cohort 1 lirilumab alone; Cohort 2: nivolumab + lirilumab; Cohort 3: azacitidine + lirilumab; Cohort 4: azacitidine + lirilumab + nivolumab | 12 participants | HMA Naïve Cohort 1, 2 low risk/int-1 MDS Cohort 3, 4 high int-2/risk MDS | No data available yet | Cohort 1, 2 could have received prior non-methylating agents. No prior anti-PD-1 or PD-L1 or immune activating drugs. Prior anti-CTLA-4 is allowed as long as the last dose was >101 days ago. Phase 2 |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (NCT02775903) | NA | Randomizes participants to either azacitidine alone OR azacitidine + durvalumab | Target MDS participants: 72 | Frontline treatment in IPSS-R intermediate >10% blasts or poor or very poor cytogenetics; OR IPSS-R High or very high risk | No data available yet | Enrollment began in June 2016. Phase 2 |
| Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure (NCT02936752) | Zeidan et al | Entinostat + Pembrolizumab | Target MDS participants: 27 | DNMTi failure (no CR, PT, HI after at least 4 cycles or progression of disease) regardless of initial IPSS-R | No data available yet | Single arm open label study excludes people who received anti-PD1 or PD-L1 or HDACi or anti-CTLA-4 or other immune activating therapy within the last 3 months |
| A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes (NCT02508870) | NA | HMA R/R MDS: atezolizumab alone OR atezolizumab + azacitidine HMA-naïve MDS: atezolizumab + azacitidine | Target MDS participants: 100 | R/R HMA: progression at any time on HMA OR no CR or PR or HI after HMA HMA naïve: frontline therapy in IPSS-R int, high or very high | No data available yet | Phase 1 |
| Trials | Authors | Treatment Arms | Estimated MDS Participants | Inclusion Criteria | Outcomes | Comments |
|--------|---------|----------------|---------------------------|-------------------|----------|----------|
| Phase I Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome (NCT02117219) | NA | MEDI4736 (Durvalumab) alone OR MEDI4236 + azacitidine OR MEDI4736 + tremelimumab OR MEDI4736 + azacitidine + tremelimumab | Target MDS participants: 73 | R/R to HMAs or couldn’t tolerate HMAs | No data available yet | Phase 1 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (NCT03066648) | NA | Decitabine + PDR001 (spartalizumab) OR Decitabine + MBG453 OR Decitabine + MBG453 + PDR001 | Target MDS participants: 70 | HMA Naive High risk MDS | No data available yet | Prior anti-PD-1/PD-L1 exposure as long as tolerated, or adverse events adequately treated with steroids >7 days of the first dose of study drug are not excluded |

HMA: hypomethylating agents; R/R: relapsed/refractory; BM: bone marrow; IPSS-R: revised international prognostic scoring system; MDS: myelodysplastic syndrome; mCR: complete marrow response; PR: partial response; PD: disease progression; HI: hematologic improvement; SD: stable disease; PSD: prolonged stable disease; alloSCT: allogeneic stem cell transplant; HDACi: histone deacetylase inhibitors; NA: not available; PD-1: programmed cell death-1; PD-L1: programmed cell death ligand 1; CTLA-4: cytotoxic T cell associated protein 4; int-1: intermediate 1; int-2: intermediate 2.

* HMA failure: failing to achieve CR, PR, or HI after at least 4 cycles.

** HMA failure defined as relapse or progression after any number of cycles or no response after at least 6 HMA cycles.

* MBG453: T cell immunoglobulin domain and mucin domain 3 (TIM-3) blocker.
Finally, as we gain a better understanding of the intricate pathophysiological basis of MDS, it is not unreasonable to assume that combining several agents together, each acting via a different mechanism, is likely to achieve more promising results, albeit at the expense of potentially more significant drug-related adverse events. This approach will likely be the main focus of future research. It is challenging to predict outcomes to therapy in MDS as they may vary with the specific population. Efforts should be directed to elicit specific characteristics to help predict response in selected populations.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] F. Haroun, S. A. Solola, S. Nassereddine, and I. Tabbara, “PD-1 signaling and inhibition in AML and MDS,” *Annals of Hematology*, vol. 96, no. 9, pp. 1441–1448, 2017.
[2] J. E. Hidalgo-Lopez, R. Kanagal-Shamanna, A. E. Quesada et al., “Progress in Myelodysplastic Syndromes: Clinico-pathologic Correlations and Immune Checkpoints,” *Clinical Lymphoma, Myeloma & Leukemia*, vol. 17, pp. S16–S25, 2017.
[3] R. Bejar, “Clinical and genetic predictors of prognosis in myelodysplastic syndrome,” *Haematologica*, vol. 99, no. 6, pp. 956–964, 2014.
[4] P. Fenaux, G. J. Mufti, E. Hellström-Lindberg et al., “Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia,” *Journal of Clinical Oncology*, vol. 28, no. 4, pp. 562–569, 2010.
[5] L. A. Anderson, R. M. Pfeiffer, O. Landgren, S. Gadalla, S. I. Berndt, and E. A. Engels, “Risks of myeloid malignancies in patients with autoimmune conditions,” *British Journal of Cancer*, vol. 100, no. 5, pp. 822–828, 2009.
[6] A. Mekinian, E. Grignano, T. Braun et al., “Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: A French multicentre retrospective study,” *Rheumatology*, vol. 55, no. 2, pp. 291–300, 2015.
[7] S. Y. Kristinsson, M. Björkholm, M. Hultcrantz, Å. R. Derolf, O. Landgren, and L. R. Goldin, “Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes,” *Journal of Clinical Oncology*, vol. 29, no. 21, pp. 2987–2993, 2011.
[8] A. Glenth, A. Ørskov, J. Hansen et al., “Immune Mechanisms in Myelodysplastic Syndrome,” *International Journal of Molecular Sciences*, vol. 17, no. 12, 2016.
[9] D. E. Epperson, R. Nakamura, Y. Saunthararajah, J. Melenhorst, and A. Barrett, “Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process,” *Leukemia Research*, vol. 25, no. 12, pp. 1075–1083, 2001.
[10] L. Wu, X. Li, C. Chang, S. Ying, Q. He, and Q. Pu, “Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome,” *International Journal of Laboratory Hematology*, vol. 30, no. 5, pp. 390–399, 2008.
[11] V. Čukrová, R. Neuwirtová, L. Doležalová et al., “Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome,” *Experimental Hematology*, vol. 37, no. 3, pp. 386–394, 2009.
[12] I. Gañán-Gómez, Y. Wei, D. T. Starczynowski et al., “Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes,” *Leukemia*, vol. 29, no. 7, pp. 1458–1469, 2015.
[13] M. Kitagawa, I. Saito, T. Kuwata et al., “Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes,” *Leukemia*, vol. 11, no. 12, pp. 2049–2054, 1997.
[14] G. E. G. Verhoeff, P. De Schouver, J. L. Ceuppens, J. Van Damme, W. Goossens, and M. A. Boogaerts, “Measurement of serum cytokine levels in patients with myelodysplastic syndromes,” *Leukemia*, vol. 6, no. 12, pp. 1268–1272, 1992.
[15] J. Maciejewski, C. Selleri, S. Anderson, and N. S. Young, “Fas antigen expression on CD3+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro,” *Blood*, vol. 85, no. 11, pp. 3183–3190, 1995.
[16] A. Kondo, T. Yamashita, H. Tamura et al., “Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes,” *Blood*, vol. 116, no. 7, pp. 1124–1131, 2010.
[17] S. Y. Kordasti, W. Ingram, J. Hayden et al., “CD4+ CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS),” *Blood*, vol. 110, no. 3, pp. 847–850, 2007.
[18] Z. Zhang, X. Li, J. Guo et al., “Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes,” *European Journal of Haematology*, vol. 90, no. 5, pp. 375–384, 2013.
[19] H. J. Jiang, R. Fu, H. Q. Wang et al., “Increased circulating of myeloid-derived suppressor cells in myelodysplastic syndrome,” *Chinese Medical Journal*, vol. 126, pp. 2582–2584, 2013.
[20] X. Chen, E. A. Eksioglu, J. Zhou et al., “Induction of myelodysplasia by myeloid-derived suppressor cells,” *The Journal of Clinical Investigation*, vol. 123, no. 11, pp. 4595–4611, 2013.
[21] C. I. Maratheftis, E. Andreakos, H. M. Moutsopoulos, and M. Voulgarelis, “Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes,” *Clinical Cancer Research*, vol. 13, no. 4, pp. 1154–1160, 2007.
[22] T. Kawai and S. Akira, “The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors,” *Nature Immunology*, vol. 11, no. 5, pp. 373–384, 2010.
[23] D. T. Starczynowski, F. Kuchenbauer, and B. Argiropoulos, “Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype,” *Nature Medicine*, vol. 16, no. 1, pp. 49–58, 2010.
[24] V. Ambros, “The functions of animal microRNAs,” *Nature*, vol. 431, no. 7006, pp. 350–355, 2004.
[25] S. Dimicoli, Y. Wei, C. Bueso-Ramos et al., “Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes,” *PLoS ONE*, vol. 8, no. 8, Article ID e71120, 2013.
[26] G. M. Rigolin, J. Howard, A. Buggins et al., “Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes,” *British Journal of Haematology*, vol. 107, no. 4, pp. 844–850, 1999.
[27] L. Ma, M. Delforge, V. Van Duppen et al., “Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes,” *Leukemia*, vol. 18, no. 9, pp. 1451–1456, 2004.
A. Palumbo, M. Mateos, J. S. Miguel et al., “Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase 3 KEYNOTE-185 study,” *Annals of Oncology*, vol. 27, 6, 2016.

H. Yang, C. Bueso-Ramos, C. DiNardo et al., “Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents,” *Leukemia*, vol. 28, no. 6, pp. 1280–1288, 2014.

M. Dail, L. Yang, C. Green, C. Ma, A. Roberts, E. Kadel et al., “Distinct patterns of PD-L1 and PD-L2 expression by tumor and non-tumor cells in patients with MM,” *MDS*, vol. 128, no. 22, pp. 1340–1340, 2016.

D. A. Sallman and M. L. Davila, *Is Disease-Specific Immunotherapy a Potential Reality for MDS? Clinical Lymphoma Myeloma and Leukemia*, vol. 17, 2017.

B. D. Cheson, P. L. Greenberg, J. M. Bennett et al., “Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia,” *Blood*, vol. 108, no. 2, pp. 419–425, 2006.

G. Garcia-Manero, M. S. Tallman, G. Martinelli et al., “Pembrolizumab, a PD-1 inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment,” *American Society of Hematology*, vol. 2016, 2016.

A. M. Zeidan, M. A. Khafan-Dabaja, and R. S. Komrokji, “Stabilization of myelodysplastic syndromes (MDS) following hypomethylating agent (HMA)s failure using the immune checkpoint inhibitor ipilimumab: a phase I trial,” *Blood*, vol. 126, 2015.

J. Wrangle, W. Wang, A. Koch et al., “Alterations of immune response of non-small cell lung cancer with Azacytidine,” *Oncotarget*, vol. 4, no. 11, pp. 2067–2079, 2013.

D. Roulois, H. Loo Yau, R. Singhania et al., “DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts,” *Cell*, vol. 162, no. 5, pp. 961–973, 2015.

K. B. Chiappinelli, P. L. Strissel, A. Desrichard et al., “Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses,” *Cell*, vol. 162, no. 5, pp. 974–986, 2015.

K. B. Chiappinelli, C. A. Zahnnow, N. Ahuja, and S. B. Baylin, “Combining epigenetic and immunotherapy to combat cancer,” *Cancer Research*, vol. 76, no. 7, pp. 1683–1689, 2016.

G. Garcia-Manero, N. G. Daver, and G. Montalban-Bravo, “A phase II study evaluating the combination of nivolumab or ipilimumab with azacitidine in patients with previously treated or untreated myelodysplastic syndromes,” *American Society of Hematology*, Dec 2016.

P. Boddhu, H. Kantarjian, G. Garcia-Manero, J. Allison, P. Sharma, and N. Daver, “The emerging role of immune checkpoint based approaches in AML and MDS,” *Leukemia & Lymphoma*, pp. 1–13, 2017.

J. Sunshine and J. M. Taube, “PD-1/PD-L1 inhibitors,” *Current Opinion in Pharmacology*, vol. 23, pp. 32–38, 2015.

N. Chokr, H. Farooq, and E. Guadalupe, “Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab,” *Reports in Oncological Medicine*, vol. 2018, 4 pages, 2018.

J. D. Wolchok, “PD-1 Blockers,” *Cell*, vol. 162, no. 5, p. 937, 2015.

L. A. Raedler, *Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma*, 2015, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665056/.

A. M. Lesokhin, S. M. Ansell, P. Armand et al., “Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase IIb study,” *Journal of Clinical Oncology*, vol. 34, no. 23, pp. 2698–2704, 2016.